Table 4.
Linear mixed effect regression models predicting change in weight, SBP or DBP from baseline value, treatment visit, whether or not the patient was on antihypertensive medication at baseline, and whether or not the participant is still in TDR, adjusted for age, sex, study centre and practice list size and a random effect for patient
| Week | Weight | SBP | DBP | |||
|---|---|---|---|---|---|---|
| Adjusted mean change (95 CI%) | p value | Adjusted mean change (95 CI%) | p value | Adjusted mean change (95 CI%) | p value | |
| 1 | −5.40 (−7.17, −3.62) | <0.0001 | −9.52 (−14.08, −4.95) | 0.0001 | −3.57 (−6.42, −0.71) | 0.0161 |
| 3 | −8.07 (−9.84, −6.30) | <0.0001 | −12.46 (−17.03, −7.88) | <0.0001 | −4.63 (−7.49, −1.77) | 0.0018 |
| 5 | −10.25 (−12.03, −8.48) | <0.0001 | −11.53 (−16.10, −6.95) | <0.0001 | −4.48 (−7.34, −1.62) | 0.0025 |
| 7 | −12.27 (−14.04, −10.50) | <0.0001 | −13.01 (−17.56, −8.44) | <0.0001 | −5.39 (−8.24, −2.54) | 0.0003 |
| 9 | −13.67 (−15.43, −11.91) | <0.0001 | −14.40 (−18.92, −9.87) | <0.0001 | −6.81 (−9.63, −3.98) | <0.0001 |
| 11 | −14.83 (−16.58, −13.08) | <0.0001 | −15.01 (−19.48, −10.53) | <0.0001 | −6.38 (−9.17, −3.59) | <0.0001 |
| 13 | −15.27 (−17.01, −13.54) | <0.0001 | −12.99 (−17.39, −8.58) | <0.0001 | −5.46 (−8.21, −2.71) | 0.0001 |
| 15 | −15.82 (−17.55, −14.10) | <0.0001 | −14.85 (−19.21, −10.49) | <0.0001 | −6.10 (−8.81, −3.39) | <0.0001 |
| 17 | −15.94 (−17.66, −14.23) | <0.0001 | −16.28 (−20.60, −11.95) | <0.0001 | −6.83 (−9.52, −4.14) | <0.0001 |
| 19 | −15.67 (−17.38, −13.96) | <0.0001 | −14.38 (−18.69, −10.08) | <0.0001 | −5.93 (−8.60, −3.25) | <0.0001 |
| 20 | −15.43 (−17.15, −13.72) | <0.0001 | −14.45 (−18.77, −10.14) | <0.0001 | −5.65 (−8.33, −2.96) | 0.0001 |
| p for week overall | <0.0001 | <0.0001 | 0.0008 | |||
| On antihypertensives at baseline | −0.62 (−1.97, 0.72) | 0.3638 | 10.60 (7.22, 13.98) | <0.0001 | 4.20 (2.08, 6.32) | 0.0001 |
| In TDR | 0.73 (0.17, 1.30) | 0.0113 | −1.44 (−3.33, 0.45) | 0.1350 | −0.43 (−1.66, 0.79) | 0.4868 |
Interactions of visit and baseline antihypertensive medication, visit and being in TDR and the three-way interaction of visit, being in TDR and baseline antihypertensive medication were not significant and have been removed from the model
Number of participants contributing to models: 138 for weight change, 137 for SBP and DBP